145 related articles for article (PubMed ID: 34952479)
1. T cell immune awakening in response to immunotherapy is age-dependent.
Salih Z; Banyard A; Tweedy J; Galvani E; Middlehurst P; Mills S; Weightman J; Gupta A; Lorigan PC; Zhou C; Dhomen N; Valpione S; Marais R
Eur J Cancer; 2022 Feb; 162():11-21. PubMed ID: 34952479
[TBL] [Abstract][Full Text] [Related]
2. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
3. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy.
Valpione S; Galvani E; Tweedy J; Mundra PA; Banyard A; Middlehurst P; Barry J; Mills S; Salih Z; Weightman J; Gupta A; Gremel G; Baenke F; Dhomen N; Lorigan PC; Marais R
Nat Cancer; 2020 Feb; 1(2):210-221. PubMed ID: 32110781
[TBL] [Abstract][Full Text] [Related]
4. Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.
El Meskini R; Atkinson D; Kulaga A; Abdelmaksoud A; Gumprecht M; Pate N; Hayes S; Oberst M; Kaplan IM; Raber P; Van Dyke T; Sharan SK; Hollingsworth R; Day CP; Merlino G; Weaver Ohler Z
Mol Cancer Res; 2021 Aug; 19(8):1422-1436. PubMed ID: 33888600
[TBL] [Abstract][Full Text] [Related]
5. Peripheral CD8
Fairfax BP; Taylor CA; Watson RA; Nassiri I; Danielli S; Fang H; Mahé EA; Cooper R; Woodcock V; Traill Z; Al-Mossawi MH; Knight JC; Klenerman P; Payne M; Middleton MR
Nat Med; 2020 Feb; 26(2):193-199. PubMed ID: 32042196
[TBL] [Abstract][Full Text] [Related]
6. Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy.
Vanmeerbeek I; Borras DM; Sprooten J; Bechter O; Tejpar S; Garg AD
Genes Immun; 2021 Jun; 22(2):108-119. PubMed ID: 34079092
[TBL] [Abstract][Full Text] [Related]
7. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
[TBL] [Abstract][Full Text] [Related]
8. Clonality of CD4
Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
Front Immunol; 2019; 10():1336. PubMed ID: 31275310
[TBL] [Abstract][Full Text] [Related]
9. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
10. Molecular patterns of resistance to immune checkpoint blockade in melanoma.
Lauss M; Phung B; Borch TH; Harbst K; Kaminska K; Ebbesson A; Hedenfalk I; Yuan J; Nielsen K; Ingvar C; Carneiro A; Isaksson K; Pietras K; Svane IM; Donia M; Jönsson G
Nat Commun; 2024 Apr; 15(1):3075. PubMed ID: 38594286
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
Gaißler A; Meldgaard TS; Heeke C; Babaei S; Tvingsholm SA; Bochem J; Spreuer J; Amaral T; Wagner NB; Klein R; Meier F; Garbe C; Eigentler TK; Pawelec G; Claassen M; Weide B; Hadrup SR; Wistuba-Hamprecht K
Front Immunol; 2022; 13():906352. PubMed ID: 35874702
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
Rose TL; Weir WH; Mayhew GM; Shibata Y; Eulitt P; Uronis JM; Zhou M; Nielsen M; Smith AB; Woods M; Hayward MC; Salazar AH; Milowsky MI; Wobker SE; McGinty K; Millburn MV; Eisner JR; Kim WY
Br J Cancer; 2021 Oct; 125(9):1251-1260. PubMed ID: 34294892
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
Klein S; Ghersi D; Manns MP; Prinz I; Cornberg M; Kraft ARM
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641478
[TBL] [Abstract][Full Text] [Related]
15. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.
Yan C; Ma X; Guo Z; Wei X; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao G; Gao X; Wang T; Jiang Y; Wang P; Pang Q; Zhang W
Oncoimmunology; 2022; 11(1):2025668. PubMed ID: 35036077
[TBL] [Abstract][Full Text] [Related]
16. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
Cham J; Zhang L; Kwek S; Paciorek A; He T; Fong G; Oh DY; Fong L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376721
[TBL] [Abstract][Full Text] [Related]
17. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
[TBL] [Abstract][Full Text] [Related]
18. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
[TBL] [Abstract][Full Text] [Related]
19. A multi-omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti-PD1 response in solid tumors.
Kumar N; Papillon-Cavanagh S; Tang H; Wang S; Stromko C; Ho CP; Soni-Sheth S; Vasquez-Grinnell S; Broz ML; Tenney DJ; Wichroski MJ; Walsh AM; Hu Y; Benci JL
Int J Cancer; 2022 Dec; 151(11):2043-2054. PubMed ID: 35932450
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8
Watson RA; Tong O; Cooper R; Taylor CA; Sharma PK; de Los Aires AV; Mahé EA; Ruffieux H; Nassiri I; Middleton MR; Fairfax BP
Sci Immunol; 2021 Oct; 6(64):eabj8825. PubMed ID: 34597125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]